The association between MTHFR polymorphism and cervical cancer

Cervical cancer is an extremely prevalent disease worldwide. The purpose of this study was to illustrate the relationship between methylenetetrahydrofolate reductase (MTHFR) polymorphisms or methionine synthase reductase (MTRR) polymorphisms and cervical cancer. There were 372 women who performed genetic and folic acid assessments. For the MTHFR C677T, there was no significant difference in the distribution of C allele and T allele in the three groups. However, the mutant C allele of MTHFR A1298C was significantly higher in the cancer group than in the normal group. Similarly, the mutant G allele of MTRR A66G was also higher than the normal group. The serum folic acid levels were gradually decreased with the development of cervical lesions. Serum folate levels in 4-9 ng/ml and <= 4 ng/ml were both significantly associated with cervical cancer risk. However, the MTHFR C677T polymorphism was not associated with the risk of cervical cancer or CIN. In contrast, the MTHFR A1298C polymorphism could increase the risk of both cervical cancer and CIN. In addition, the MTRR A66G polymorphism was only associated with the risk of cervical cancer but not CIN.